Drug Trial Radar · NCT05861297
Immune Thrombocytopenia Management in Adults
Last checked: Nov 20, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
467
Planned (sponsor's estimate)
Start
May 5, 2020
Primary completion
Jan 18, 2024
Study completion Apr 2, 2024
Sponsor
- Lead sponsor
- Nahda UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Immune thrombocytopenia treatment has evolved recently. However, none of treatments have only benefits without drawbacks. This study compares the clinical outcomes and adverse drug patterns of different treatment options. Medications which will be assessed during the current study are High Dose-dexamethasone (HD-DXM) (control group), Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim.
Conditions
- Immune Thrombocytopenia Purpura
Interventions
DexamethasoneDrug
Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months
Prednisolone and AzathioprineDrug
the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.
RituximabDrug
The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month
EltrombopagDrug
The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months
RomiplostimDrug
The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- total patients who achieved sustained and overall responseTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
EL-Kasr elineiy
Cairo, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.